Thymectomy for myasthenia gravis

Area of Science:

• Neurology
• Surgical Oncology

Background:

• Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease.
• Medical management of MG can be challenging, with some patients showing poor response.
• Thymectomy is a surgical option for MG, but its efficacy and safety require ongoing evaluation.

Purpose of the Study:

• To review the outcomes of medical management versus thymectomy in patients with myasthenia gravis.
• To assess the safety and effectiveness of thymectomy in a cohort of MG patients.

Main Methods:

• Retrospective review of 71 patients diagnosed with myasthenia gravis.
• Analysis of treatment outcomes for patients managed medically versus those who underwent thymectomy.
• Evaluation of postoperative complications and mortality rates.

Main Results:

• Of 71 patients, 18 underwent thymectomy after initial medical management.
• Twenty-three patients had poor response to drugs; seven died from respiratory failure.
• Thymectomy was beneficial in 16 of 18 surgically treated patients, despite seven experiencing significant postoperative respiratory complications requiring tracheostomy in nine cases.

Conclusions:

• Thymectomy is an effective and safe treatment for myasthenia gravis.
• Indications for thymectomy include young patients with early disease and those refractory to drug treatment.
• The transcervical approach to thymectomy proved satisfactory in the cases reviewed.